Verisante Technology Inc (VRS.H)

[weekend farmer]

New News for VRSEF February 26, 2014
Announces Hiring of Global Sales Director and Sales Representative for Canada

VANCOUVER, BRITISH COLUMBIA - Verisante Technology, Inc. (TSX-V: VRS, OTCQX: VRSEF) (the “Company” or “Verisante”), a leader in cancer detection technology, announced today that the Company has hired Jason Mangler as Director of Sales to guide the Company’s world-wide sales and marketing strategy. Verisante has also hired Kim Ellis, as the Company’s Sales Representative for Western Canada.

“I’m excited to be part of the Verisante organization and am looking forward to playing a leadership role in Sales and Marketing for the Company,” says Jason Mangler. “I am committed to bringing innovative solutions to the market that I have spent the past decade serving.”

Jason joins Verisante after more than 15 years of sales and sales management experience, ten of those in progressive roles with General Electric. As Director of Sales, Jason will be responsible for developing and executing Verisante’s market development and sales plans. He will supervise the Company’s sales and marketing team to identify market opportunities and fulfill market needs, ensure delivery of quality solutions, and meet both short and long term business goals.

Joining Jason on the Sales team is Kim Ellis, who has extensive experience with technical sales and training, and who, as a melanoma survivor, also has a depth of knowledge of skin cancer.

“I’m passionate about this technology because I know it works. After all else was said and done, it was an Aurascan that helped identify one of my skin lesions as cancerous,” said Kim Ellis. “I’m excited to help bring this technology to medical professionals across Canada.”

“Verisante is proud to welcome Jason and Kim to the Company as we prepare our full market release of Aura and continue our sales efforts to the research community,” said Thomas Braun, President and CEO.

Following an extensive limited market release and testing year in 2013, Verisante is focused on developing and materializing commercial revenue generating opportunities for the Company. Verisante is gearing up for a full product launch for Aura™ in Canada and Europe while concurrently pursuing FDA approval for the product in the United States. The Company is also continuing the completion of a Verisante Core™ device for the detection of lung cancer to be submitted for regulatory approvals. The Core, which utilizes the same proprietary cancer detection platform as Aura™, has the potential to be used for the detection of other internal cancers including colorectal and cervical.
http://www.verisante.com/news/124/verisante-technology-inc-grows-sales-and-marketing-team/